RARRES1

protein-coding

retinoic acid receptor responder 1

Gene summary

This gene was identified as a retinoid acid (RA) receptor-responsive gene. It encodes a type 1 membrane protein. The expression of this gene is upregulated by tazarotene as well as by retinoic acid receptors. The expression of this gene is found to be downregulated in prostate cancer, which is caused by the methylation of its promoter and CpG island. Alternatively spliced transcript variant encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

MANE transcript

NM_206963.2

Inheritance

—

ClinVar variants

U:58B:5

Top phenotype

—

gnomAD constraint

pLI —, LoF o/e 1.02

Max pathogenic AF

—

Genomic locus

chr3:158,696,892-158,732,489

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~35.6 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

No GenCC data available for this gene.

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to RARRES1 variants in ClinVar

1 Conditions Cataloged
not specifiedTotal: 57

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_206963.2. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
0
missense
52
clinvar
5
clinvar
57
nonsense
0
start loss
0
frameshift
0
splice donor/acceptor (+/-2bp)
6
clinvar
6
Total00585063
Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 20 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_206963.2RefSeqNP_996846.16MANE Select
ENST00000237696.10EnsemblENSP00000237696.56MANE Select
NM_002888.4RefSeqNP_002879.24Standard
ENST00000479756.1EnsemblENSP00000418556.14Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Biological Process

  • negative regulation of cell population proliferation

Cellular Component

  • integral component of membrane
  • extracellular exosome

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000237696
Coding exons
6
Length
35805
Individuals with no LoFs
125696
Homozygous LoFs
0
Heterozygous LoFs
50
Defined
125746
p
0.000199
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense0.823981240.7920.000006451857
Missense (PolyPhen)2334.4610.66742504
Synonymous0.8853643.40.8290.00000225579
Loss of Function-0.08181312.71.026.06e-7154

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000870.00086rare
Latino/Admixed American0.000440.00043rare
Ashkenazi Jewish00.0absent
East Asian0.0000550.000054rare
Finnish00.0absent
European (Non-Finnish)0.000120.00011rare
South Asian0.000180.00016rare
Other0.000500.00049rare

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Inhibitor of the cytoplasmic carboxypeptidase AGBL2, may regulate the alpha-tubulin tyrosination cycle. {ECO:0000269|PubMed:21303978}.;

Recessive Scores

pRec
0.0818

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
N
Indispensability score
0.0454

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.